---

Discussion

Kate Burvish:

The short version is that CVS is reversing part of its vertical-integration strategy. The proposed CVS Health company would retain Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The separate CVS Pharmacy company would contain roughly 9,000 retail pharmacies, mail pharmacy, MinuteClinic—including virtual care—and Health100. So this is not a simple split between “healthcare” and “pharmacies.” One company keeps the insurer, the pharmacy-benefit manager, specialty pharmacy and several care businesses; the other gets the consumer-facing pharmacy and clinic platform.

Sofia Jadler:

And the word “proposed” matters. This is an announced intention, not a completed transaction. CVS still needs final board approval, an effective Form 10 registration statement with the Securities and Exchange Commission, tax confirmation for the intended tax-free treatment and other customary conditions. Existing shareholders are expected to receive ownership in both companies, but the materials do not yet settle the distribution ratio, debt allocation, trading symbols or precise capitalization. Those details will determine whether this is a meaningful separation or two companies tied together by extensive obligations.

Priya Merlan:

For patients, the organizational chart is less important than the journey through it. A person might have Aetna insurance, use Caremark for prescription benefits, obtain a specialty medication through one CVS channel and visit MinuteClinic through another. CVS says important relationships will continue through commercial agreements and that it will preserve integration where it supports affordability and outcomes. But CVS Specialty stays in CVS Health while retail and mail pharmacy move to CVS Pharmacy. That distinction could affect medication access, patient support and communication with prescribers.

Red Velhouse:

So the first promise is sharper focus, but the first risk is that the businesses remain dependent on one another. Kate, is this mainly an economic improvement, or mainly a way to make the businesses easier for investors to value?

Kate Burvish:

It can be both, but the investor benefit is the easiest one to identify. CVS currently combines businesses with very different economics: insurance underwriting, pharmacy-benefit contracting, specialty pharmacy, value-based care, retail dispensing and clinics. Separate reporting could show which managers are creating value and which businesses are consuming capital. It might also let the pharmacy company invest in stores, digital care or labor without competing directly with Aetna’s medical-cost demands. But clarity is not relief. The separation could bring duplicated corporate functions, new contracting expenses, weaker purchasing leverage and the friction of negotiating with a former sibling.

Sofia Jadler:

And “independent” does not mean “unrelated.” The companies may preserve selected relationships through commercial agreements. Each agreement will have to answer who gets access to what data, on what terms and at what price. Transfer pricing between the businesses could become a recurring dispute. If the contracts are too loose, coordination suffers. If they are too intimate, critics can argue that the breakup changed the legal form without changing the underlying power structure.

Red Velhouse:

That tension leads to the policy question. Does separating the retail pharmacy from Caremark reduce conflicts of interest, even though Caremark remains one of the largest pharmacy-benefit managers?

Sofia Jadler:

It could reduce one visible conflict, but it would not resolve the broader legal and policy concerns surrounding pharmacy-benefit managers, or PBMs. The Federal Trade Commission has highlighted concentration and vertical integration. The three largest PBMs—Caremark, Express Scripts and Optum Rx—have been estimated to process roughly 80 percent of U.S. prescriptions, while another FTC estimate found that the six largest managed nearly 95 percent in 2023. Those figures use different definitions, so they are not interchangeable. Still, they point to a concentrated market. A corporate separation does not create a new competitor or prohibit complex contracting by itself.

Kate Burvish:

Exactly. The economic issue is not ownership alone; it is bargaining power. Caremark will still negotiate with manufacturers, insurers, employers and pharmacies at enormous scale. Separating the retail chain might make affiliated-pharmacy treatment easier to scrutinize, but it could also remove purchasing or operating efficiencies. Employers are showing interest in alternatives: a 2026 survey found that 46 percent were using a PBM outside the three largest firms, up from 37 percent the year before. That suggests demand for transparency and claims data, but it does not prove this breakup will lower prices.

Priya Merlan:

And from the clinical side, we should resist promising either improvement or harm before we see the operating agreements. Continuity of care depends on practical details: whether records move smoothly, whether clinicians can see relevant medication information, whether prior authorization remains understandable and whether specialty prescriptions reach patients on time. The announcement does not establish lower patient costs, higher pharmacy reimbursement or better outcomes. Those are hypotheses to test through access, adherence, wait times, medication errors and patient experience.

Red Velhouse:

Priya, which patients are most exposed to those coordination risks?

Priya Merlan:

Patients with complex or recurring treatment needs are the obvious group to watch—not because we know they will be harmed, but because they rely on coordination. Someone using a specialty medication may interact with a prescriber, a benefits manager, a specialty pharmacy, a retail location and a clinic. Splitting those functions can create clearer accountability, but it can also create more handoffs. MinuteClinic users raise a related question: if clinics and virtual care move to CVS Pharmacy while the insurer and PBM remain in CVS Health, will referrals, coverage information and follow-up still feel seamless? The answer will depend on systems and contracts, not corporate names.

Kate Burvish:

That is also where the retail company’s economics matter. It starts with reimbursement pressure, online competition, labor and operating costs, and declining front-store traffic as prescriptions move toward delivery. A standalone company might finally be judged directly on those constraints instead of having its results blended with insurance and PBM profits. But if the retail business loses internal support or purchasing leverage, its costs could rise even as its performance becomes easier to read.

Red Velhouse:

Sofia, CVS is also challenging state laws in Arkansas and Tennessee that restrict common ownership or operation of pharmacies and PBMs. Does that make the breakup a response to regulation by another name?

Sofia Jadler:

The careful answer is that regulation is part of the environment, but causation is unproven. CVS executives have characterized the move as a strategic choice rather than a response to regulation. At the same time, the company is litigating restrictions that could affect its business model; Tennessee’s law is described in litigation materials as taking effect in July 2028, subject to ongoing proceedings. Separating the companies could be rhetorically useful in those disputes, but it does not automatically satisfy a state law. Courts will examine statutory language, ownership, control and the actual operating arrangements.

Kate Burvish:

That distinction is important economically too. A breakup can change the allocation of risk without changing the market’s structure. CVS may have two stock prices, two boards and two sets of incentives, while patients and pharmacies still encounter Caremark’s negotiating power and contractual rules. The real test is whether accountability becomes more credible. If each company can blame the other for reimbursement, access or service problems, we have not created accountability; we have created a relay race with no finish line.

Priya Merlan:

Workers will be part of that accountability story. Pharmacists, clinic workers, call-center staff and corporate employees may face new reporting lines, systems and performance targets. The announcement does not tell us whether efficiency will come from better focus or from shifting costs and reducing staff. For patients, staffing is not an abstract expense. Adequate pharmacist and clinic staffing affects counseling, responsiveness and the ability to catch problems.

Red Velhouse:

Let’s make the test concrete. What would show that the breakup worked, rather than simply moving profits and costs between two public companies?

Kate Burvish:

I would start with comparable pro forma financial reporting: standalone revenue, operating costs, debt service, separation expenses and the terms of intercompany agreements. Then I would track outcomes that cannot be cosmetically shifted—pharmacy access, prescription fulfillment, employer retention, investment and reimbursement trends. If the retail company improves only because the health company absorbs costs, that is not an efficiency gain. If Caremark’s margins rise while employers and pharmacies receive worse terms, that is not evidence of consumer benefit.

Sofia Jadler:

Legally, the Form 10 and separation agreements deserve close attention. They should reveal how debt and liabilities are allocated, what data each company can use, how disputes are resolved, how network access is handled and how specialty-pharmacy transactions are governed. Tax opinions, required consents and state litigation developments also matter. The clever maneuver would be to preserve enough contractual integration to retain operational benefits while presenting enough independence to satisfy investors and regulators. Whether that balance holds should be visible in the documents.

Priya Merlan:

For patients, the measures should be just as concrete: medication-delivery reliability, prior-authorization delays, continuity of specialty treatment, clinic follow-up, complaints and avoidable interruptions. We should distinguish relative improvements from meaningful absolute ones. A small percentage change can sound impressive while affecting few people, while a modest delay can be devastating for someone whose treatment is time-sensitive. The medical question is not whether the new structure sounds coordinated. It is whether people receive appropriate care more reliably.

Red Velhouse:

So CVS is pursuing a corporate separation that may preserve substantial healthcare integration. Management says two focused and agile companies will allocate capital more effectively. Critics can see the move as an admission that the integrated model became too complex, while the remaining PBM concentration means the central policy issue survives. The target is the first half of 2028, but the important story now is in the details.

Red Velhouse:

The central unresolved issue is whether CVS can gain clearer accountability without losing the coordination that vertical integration was supposed to provide—and whether separating retail pharmacy from Caremark changes real market power or mainly changes the corporate map. Watch for the Form 10, debt and tax arrangements, intercompany service agreements, data-sharing rules, specialty-pharmacy and network terms, state litigation, employee plans and the first pro forma financial disclosures. Those developments will tell us whether this is an economic reset or a carefully engineered rearrangement. Sources and references for this discussion are available with the episode at Factolio.com.

---

Sources and References

These sources supported the factual material used in this discussion. Factolio’s panel discussion is AI-generated from researched evidence and is written in original language.

1. CVS Health — CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare (PRIMARY)
2. U.S. Securities and Exchange Commission — CVS Health Corporation Form 10-Q for the quarter ended September 30, 2026 (PRIMARY)
3. CVS Health — Q3 2026 Investor Update Presentation (PRIMARY)
4. Reuters — CVS to break up $117 billion business, separating pharmacies from insurance; shares fall (NEWS)
5. Healthcare Dive — CVS to split into two companies in stunning strategic about-face (NEWS)
6. U.S. Securities and Exchange Commission — CVS Health Form 10-Q: segment descriptions and operating results (PRIMARY)
7. U.S. Securities and Exchange Commission — CVS Health Form 10-Q: Health Services and Pharmacy & Consumer Wellness disclosures (PRIMARY)
8. Federal Trade Commission — FTC Releases Interim Staff Report on Prescription Drug Middlemen (PRIMARY)
9. JAMA — Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at US Retail Pharmacies (DATA)
10. Axios — More employers are dropping the largest PBMs (NEWS)
11. Associated Press — CVS and Express Scripts sue Arkansas over restriction on pharmacy benefit managers (NEWS)
12. Tennessee Lookout — CVS Tennessee Complaint Final (PRIMARY)